Keeping checkpoint kinases in line: new selective inhibitors in clinical trials
- 12 August 2008
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 17 (9), 1331-1340
- https://doi.org/10.1517/13543784.17.9.1331
Abstract
(2008). Keeping checkpoint kinases in line: new selective inhibitors in clinical trials. Expert Opinion on Investigational Drugs: Vol. 17, No. 9, pp. 1331-1340. doi: 10.1517/13543784.17.9.1331Keywords
This publication has 57 references indexed in Scilit:
- Targeted cancer therapies based on the inhibition of DNA strand break repairOncogene, 2007
- The DNA Damage Response: Ten Years AfterMolecular Cell, 2007
- The Chk2 protein kinaseDNA Repair, 2004
- Chk1 Mediates S and G2 Arrests through Cdc25A Degradation in Response to DNA-damaging AgentsJournal of Biological Chemistry, 2003
- Ataxia-telangiectasia-mutated (ATM) and NBS1-dependent Phosphorylation of Chk1 on Ser-317 in Response to Ionizing RadiationJournal of Biological Chemistry, 2003
- Chk1-deficient tumour cells are viable but exhibit multiple checkpoint and survival defectsThe EMBO Journal, 2003
- Regulation of G2/M events by Cdc25A through phosphorylation-dependent modulation of its stabilityThe EMBO Journal, 2002
- Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G 2 checkpointsProceedings of the National Academy of Sciences, 2002
- Rapid Destruction of Human Cdc25A in Response to DNA DamageScience, 2000
- Maintenance of G2 arrest in the Xenopus oocyte: a role for 14-3-3-mediated inhibition of Cdc25 nuclear importThe EMBO Journal, 1999